Search
Filter Results
Displaying 531–540 of 749 for “retinal diseases”
-
Treatment for AMD depends on its stage. For wet AMD, several treatments can help preserve vision. For geographic atrophy, the first treatments were approved in 2023. For early and intermediate dry AMD, options remain limited, which is why research is so urgent. Use the chart below to see what is available at each stage, then talk with your eye doctor about what is right for you.
-
The Foundation Fighting Blindness Advocacy in Focus highlights how we bring our mission into the policy arena, shaping decisions and empowering our community to create lasting change.
-
Jan 27, 2025
Eva Lou Schroeder Watson's Enduring Legacy
Beacon StoriesEva Watson’s life was marked by her dedication to advancing medical research for blinding diseases, and her generous bequest to the Foundation Fighting Blindness ensures her advocacy will endure. Her story highlights the profound impact of her contributions to driving treatments and cures for blinding diseases.
-
Jun 5, 2024
Antabuse Moves into Clinical Trial for People with RP
Research NewsResearchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
May 16, 2024
Research NewsNo serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
Feb 2, 2024
Eye on the Cure Podcast | Episode 61: Dr. Jose Sahel
Eye on the CureDr. Jose Sahel, one of the most honored and accomplished leaders in the retinal disease research space, talks with host Ben Shaberman about his establishment and leadership of renowned ophthalmology clinical research centers at the University of Pittsburgh Medical Center and Institut de la Vision in Paris. They also discuss emerging inherited retinal disease therapies from SparingVision, a biotech co-founded by Dr. Sahel.
-
Dec 15, 2023
Eye on the Cure Podcast | Episode 58: Jason Comander
Eye on the CureJason Comander, Md, PhD, clinical researcher, surgeon, and director of the Inherited Retinal Disease Disorders Service at Mass Eye and Ear, talks to host Ben Shaberman about his administration of LUXTURNA gene therapy to RPE65 patients, his team’s re-analysis of vitamin A therapy for retinitis pigmentosa, and passion for retinal research and patient care.
-
Oct 3, 2022
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Jul 14, 2022
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas
Research NewsThe emerging treatment is gene-agnostic.
-
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
Research NewsThe Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.